High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

International Journal of Cancer

Volumn 127, Issue 1, 2010, Pages 138-147

  He, Li Ru ^a   Liu, Meng Zhong ^a   Li, Bin Kui ^a   Jia, Wei Hua ^a   Zhang, Ying ^a   Liao, Yi Ji ^a   Chen, Yang Chao ^b   Zhang, Lan Jun ^a   Guan, Xin Yuan ^a   Zeng, Yi Xin ^a   Kung, Hsiang Fu ^a,b   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemoradiotherapy; Esophageal squamous cell carcinoma; EZH2; Immunohistochemistry; Prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL; TRANSCRIPTION FACTOR EZH2; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADJUVANT THERAPY; ADULT; ARTICLE; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ECHOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOGRAPHY; ESOPHAGUS RESECTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; TUMOR BIOPSY; X RAY; ESOPHAGUS TUMOR; GENE AMPLIFICATION; GENETICS; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 77953444201     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25031     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer. J Clin 2005;55:74-108.
2. Brenner B, Ilson DH, Minsky BD. Treatment of localized esophageal cancer. Semin Oncol 2004;31:554-65.
3. Urba S. Esophageal cancer: preoperative or definitive chemoradiation. Ann Oncol 2004; 15(Suppl 4):iv93-6.
4. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-17.
5. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005; 104:1349-55.
6. Bonnetain F, Bouche O, Michel P, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Paillot B, Arveux P, Milan C, Bedenne L. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 2006;17:827-34.
7. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005;35:316-23.
8. Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishigami S, Takao S, Aikou T. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 2005;92:284-9.
9. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, Bergqvist M. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19:224-31.
10. Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M. Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 2003;10: 792-800. (Pubitemid 40486880)
11. Akimoto T, Nonaka T, Harashima K, Ishikawa H, Sakurai H, Mitsuhashi N. Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. Anticancer Res 2004;24:811-19. (Pubitemid 38625027)
12. Kim R, Inoue H, Toge T. Bax is an important determinant for radiation sensitivity in esophageal carcinoma cells. Int J Mol Med 2004;14:697-706.
13. Natsugoe S, Matsumoto M, Okumura H, Nakashima S, Sakamoto F, Sakita H, Baba M, Takao S, Aikou T. Bax and Bcl-X(L) expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Lett 2001;174:91-7.
14. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21-9.
15. Tonini T, D'Andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 2008;214: 295-300. (Pubitemid 350308984)
16. Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 2000; 8:174-80. (Pubitemid 30189860)
17. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001;97:3896-901.
18. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006; 97:484-91.
19. Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005;31:376-80.
20. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, Wakiyama S, Fujita H, Shirouzu K, Mori M. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1754-8.
21. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006;12:1168-74.
22. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-73.
23. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K, Ito H. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009;45:39-46.
24. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene. EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11:8570-6.
25. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
26. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J, Kung HF. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007;46: 200-8.
27. Merola E, Mattioli E, Minimo C, Zuo W, Rabitti C, Cicala M, Caviglia R, Pollice L, Gabbrielli A, Giordano A, Claudio PP. Immunohistochemical evaluation of pRb2/ p130. VEGF, EZH2, p53, p16, p21waf-1, p27, and. PCNA in. Barrett's esophagus. J Cell Physiol 2006;207:512-19.
28. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2. Ki-67 and. MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008;122:595-602. (Pubitemid 350308951)
29. Xie D, Sham JS, Zeng WF, Lin HL, Bi J, Che LH, Hu L, Zeng YX, Guan XY. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol 2005;36: 777-83.
30. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125:301-13.
31. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008;14: 6790-6.
32. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-69.
33. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35.
34. Berton TR, Mitchell DL, Guo R, Johnson DG. Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation. Oncogene 2005;24: 2449-60.
35. Benadiba M, Miyake JA, Colquhoun A. Gamma-linolenic acid alters Ku80. E2F1, and bax expression and induces micronucleus formation in. C6 glioma cells in vitro. IUBMB Life 2009;61: 244-51.
36. Yamazaki K, Hasegawa M, Ohoka I, Hanami K, Asoh A, Nagao T, Sugano I, Ishida Y. Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus. J Clin Pathol 2005;58:904-10.
37. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007;67: 10657-63.
38. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005;280: 22437-44.
39. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 2004;23:4930-7.